What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
A large prospective psoriatic arthritis (PsA) study examined the enthesitis outcomes when PsA patients received conventional (cDMARDs) or targeted disease-modifying antirheumatic drugs (tDMARDs) and showed an overall 86% response rates, regardless of the medication used.
Dr. John Cush RheumNow
3 years 5 months ago
French study from 362 septic arthritis pts over 2 yrs., mean age was 64yrs, w/ high Charlson comorbidity index 3.5. Most common was Knee (39%), Staphylococcus (51%), Abx used 47d, surgery in 48%; 28% serious complications & 9.2% died https://t.co/P2nxnhDnut https://t.co/KoZoe1yib4
Dr. John Cush RheumNow
3 years 5 months ago
JAMA patient (resource) handout on Lumbar Spinal Stenosis! https://t.co/MR7aIrP0Pq https://t.co/Q6rvddbnvT
The concept of a “Still’s disease continuum” that encompasses both sJIA and AOSD is based on the many common clinical, genetic and laboratory features shared by both sJIA and AOSD.
Dr. John Cush RheumNow
3 years 5 months ago
162 #AOSD or #sJIA criteria+ pts underwent genetic testing - 31% (51/162) had a genetic variant for periodic fever Dx. 4 SJIA pts were confirmed to have FMF or TRAPS. Genetic testing may be smart, esp w/ atypical presentations https://t.co/hwZFgOL4j4 https://t.co/6y8r1Dyv1A
Dr. John Cush RheumNow
3 years 5 months ago
Abatacept Most Effective Early and in Seropositive RA
A 2 year study evaluated the efficacy and safey (drug retention) of subcutaneous ABA in active RA and showed superior responses when ABA was given to biologic-naive and seropositive RA patients.
https://t.co/WdZ3YCeGXg https://t.co/4ZjFFrVmSJ
Dr. John Cush RheumNow
3 years 5 months ago
11.5% of Crohns pts have TNFi use contraindications (either MS, CHF, neoplasia, infx risk, TNFi AE, comorbidities, SLE. Alternatively GI survey respondents use ustekinumab (76%), vedolizumab (249%), or tofacitinib (0.5%) https://t.co/NqGOislcIJ https://t.co/tqk3jF3Lxg
Dr. John Cush RheumNow
3 years 5 months ago
Cochrane metanalysis of sleep meds - 170 trials (36 interventions, 47950 pts). Doxepin, seltorexant, zaleplon well tolerated, but efficacy data is scarce. Benzodiazepines, eszopiclone, zolpidem, were more efficacious, but zolpidem more dropouts due to AEs https://t.co/8mPYmfTAaR https://t.co/DqUFcgq9AR
Placebo responses are to be expected in rheumatoid arthritis (RA) clinical trials, but are such placebo responses affected by continuing background DMARDs like methotrexate (MTX) even though there was an inadequate response (IR) to MTX?
For about one in six people considered healthy with no reports of back pain, lesions were visible on MRI in the lower spinal column and sacroiliac joint, researchers said -- a sign that rheumatologists should be cautious about diagnosing spondyloarthritis (SpA) on the basis of imaging.
Dr. John Cush RheumNow
3 years 5 months ago
Leflunomide versus azathioprine in lupus nephritis? Study of 215 bx proven LN given either LEF or AZA - Renal flares were equal (15.7% v 17.8%), as was time to flare (16 mo vs AZA 14 mo); 24-hr proteinuria, creatinine, C3 and C4 improved similarly. https://t.co/FEKwwyoJhZ https://t.co/zUyHXGjpOD
Dr. John Cush RheumNow
3 years 5 months ago
Rheumatologist Survey:
What do you rely on MOST in diagnosing Still’s disease?
Sxs? Labs? Both? Criteria? Fever? Vote here: https://t.co/L1kyWXf68I
An open-label, 2 year study evaluated the efficacy and safey (drug retention) of subcutaneous (SC) abatacept (ABA) in active rheumatoid arthritis (RA) and showed superior responses when ABA was given to biologic-naive and seropositive RA patients.
Dr. John Cush RheumNow
3 years 5 months ago
Watch: Remote Monitoring Technologies in the Management of RA
Dr. Antoni Chan interviews Dr. Johannes Knitza at EULAR 2022
https://t.co/SU9SUScHiS https://t.co/YoxQPZH5eQ
Poster Hall